RUTGERS


Cancer Institute
of New Jersey
RUTGERS HEALTH



Aims

- Provide statistical support to study planning, design and data analysis
- Support every type of cancer study, including investigator-initiated trials, population-based intervention studies, observational studies, and basic science experiments
- Support study activities including randomization, trial monitoring, interim analysis, the generation and interpretation of data analysis reports, and publications
- Develop and implement novel statistical methods for cancer research

Research Program Support (2018–2022)



Publications	
Co-Authored	140
IF >10	13

Peer-Reviewed Grants

All	29
NCI	16

CPC, CIPT



J Clin Oncol, 2023

CPC, CIPT



JAMA Oncol, 2021

CIPT



JAMA Oncol. 2020

CIPT



Blood, 2021

CMI, GICG



Genes Dev. 2020





Leading Personnel & Roles



Hao Liu, PhD Director
Survival analysis, Bayesian trials, Phase I and II trials, Basic and Population Science



Yong Lin, PhD
Faculty Statistician
Survival analysis, Phase I and II trials,
Animal Experiments and Population Science



Elizabeth Handorf, PhD (Jul 01, 2023)

New recruit



Shou-En Lu, PhD *Faculty Statistician*Mediation and moderation analysis,
Basic and Population Science



Dirk Moore, PhDFaculty Statistician
Survival analysis, Phase I and II trials,
Basic and Population Science



Shengguo Li, PhD Staff Statistician Chunxia Chen, MS Staff Statistician



Pamela Ohman-Strickland, PhD Faculty Statistician Cluster RCT, Population Science



Liangyuan Hu, PhD
Faculty Statistician
Causal inference, Bayesian analysis,
Population Science





Services & Innovation

New

- Novel statistical methods to support cancer research, e.g., early phase clinical trials, causal mediation analysis for cancer prevention and control
- Analysis of large-scale emerging datasets including genomics, metabolomics, proteomics and electronic health records
- Support for the design and analysis of population-based studies and implementation science including cluster randomized trials
- Faculty and staff recruitment plan based on needs assessment survey (see attachments)

Continuing

- Statistical support to research projects, study design, conduct and study monitoring
 - Computation, statistical analyses, data reports/publications
- Development of novel statistical methodology supporting cancer research
- Statistical review of study protocols and grant proposals
- Education and training activities
 - Annual Clinical Trial Design course for the clinical fellows in CINJ fellowship programs (BSR faculty Liu and Moore)
 - K-award support
 - All BSR faculty members are also part of SPH who participate in teaching courses





Improving Uptake of Cancer Genetic Risk Assessment in a Remote Tailored Risk Communication and Navigation Intervention: Large Effect Size but Room To Grow

Kinney⊠, O'Malley, Stroup, (CPC)

Toppmeyer (CIPT)

Lin and Lu (BSR co-authors)

J Clin Oncol, 2023 Feb 14:JCO2200751 JCO published online February 14, 2023: a randomized intervention trial on CGRA uptake among ovarian and high-risk breast cancer survivors to compare: (1) a tailored remote intervention (TCN); (2) a nontailored print brochure promoting CGRA (TP); and (3) usual care (UC) BSR faculty statisticians Lin and Lu provided critical support to the study design and data analysis. Additionally, Lin and Lu used their statistical expertise in applying multiple imputation method to perform a sensitivity analysis to study if the conclusions were consistent for some participants with unknown CGRA uptake outcomes The study showed that phone-based tailored counseling is effective in improving CGRA uptake, notably in historically underserved groups, including Hispanic, rural, and low-literacy populations

Timeline	TP	TCN
Baseline	а	а
Random assignment		
Intervention	b c	b c d e f g h
One-month postintervention	Intermediate end point assessments (perceived susceptibility, perceived severity, perceived self-efficacy, response efficacy, HBOC knowledge, fear of HBOC, defensive avoidance, cancer worry, fatalism and destiny, perceived stress, and CGRA)	

TABLE 3. Logistic Regression Model Results for Intervention Effects on CGRA Within 6 Months Modela TCN v TP TCN v UC TP v UC Outcome known OR 7.4 8.9 1.2 95% CI (3.0 to 18.3) (3.4 to 23.5) (0.4 to 4.0) < .0001 .767 < .0001 Negative outcome imputation^b OR 6.2 7.4 1.2 95% CI (2.5 to 15.2) (2.8 to 19.4) (0.4 to 4.0) < .0001 < .0001 .778 Multiple imputation^c OR 4.9 4.9 1.0 95% CI (2.351 to 10.281) (2.2 to 11.3) (0.4 to 2.6) < .0001 < .0001 .994






Association of Body Mass Index, Central Obesity, and Body Composition with Mortality among Black Breast Cancer Survivors


Qin, Zeinomar, Bandera (CPC) ⊠ Omene (CIPT)


Lin and Xu (BSR co-authors)

JAMA Oncol, 2021 10.1001/jamaoncol.2021.1499

Kaplan-Meier curves for all-cause and breast cancer-specific survival by Body Mass Index (BMI) and Waist-to-Hip Ratio (WHR)







- BSR statisticians Lin and Xu applied the advanced statistical method of the Fine and Gray subdistribution hazard model for competing risk data to analyze breast cancer-specific mortality
- The study showed that obesity and adiposity were associated with all-cause and breast cancer-specific mortality among Black breast cancer survivors, which can be useful tools for identifying high risk patients among Black women with breast cancer







Phase 1 Trial of Pembrolizumab Administered Concurrently with Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer


Jabbour (CIPT) ☑


Aisner, Malhotra (CIPT)


Lin (BSR co-author)

JAMA Oncol, 2020 6(6):848-855

- In a collaboration with CIPT members Jabbour, Aisner and Malhotra, BSR faculty biostatistician Lin provided statistical design and analysis of a phase I trial of pembrolizumab administered concurrently with chemoradiotherapy for locally advanced non–small cell lung cancer
- Lin carefully estimated the probability of dose-toxicity response curves in the sample size justification of the phase I trial and provided statistical support to the data analysis for this trial
- The study demonstrated that combined treatment with PD-1 inhibitors and chemoradiotherapy for stage III NSCLC is tolerable, with promising 12 month of PFS of 69.7%












Burkitt Lymphoma in the Modern Era: Real-world Outcomes and Prognostication Across 30 US Cancer Centers


Evens (CIPT) ☑


Lin (BSR co-author)


Blood, 2021 137(3): 374–386

- BSR faculty statistician Lin applied the advanced statistical techniques of Harrell's C concordance coefficients and nonparametric bootstrap for variable selection and assessment of model fit that are critical for the scientific result
- The study called attention to the critical prognostic factors that drive outcomes across the full continuum of adult patients with Burkitt lymphoma (BL) in the United States













Autophagy Promotes Mammalian Survival by Suppressing Oxidative Stress and p53

White (CMI) ⊠


Hu (GICG)

Moore (BSR co-author)

Genes Dev, 2020 34(9-10):688-700

BSR statistician Moore applied the Log-rank and Gehan-Breslow-Wilcoxon tests to analyze survival data for the animal experiments

The study showed that the tissue-specific roles for autophagy and functional dependencies on the p53 and NRF2 stress response mechanisms



- Atg7Δ/Δ, p53Δ/Δ mice have extended life span, delayed tissue damage and neurodegeneration compared with Atg7Δ/Δ mice
- (A) Experimental design for generation of shown murine strains
- (B) Western blot for ATG7, p62, and LC3 at the indicated times of the indicated tissues and murine strains
- (C) Kaplan-Meier survival curve of murine strains. Dotted line indicates 109 d, when the first lymphoma was identified in p53Δ/Δ mice. (n.s.) Not significant; (*) P < 0.05; (**) P < 0.01; (****) P < 0.0001 (log-rank test and Gehan-Breslow-Wilcoxon test as indicated).Data are presented as mean ± SD. n = 6. *P < 0.001; **P < 0.0001, mixed model analysis with Bonferroni's adjusted P values
- (D) Percentage distribution for the cause of death of murine strains
- (E) Representative Histology of shown tissues of various murine strains
- (F) Kaplan-Meier survival curve of murine strains that died after 109d. Black dots on the survival curve indicate the censoring times that mice died of no tumor development. (****) P < 0.0001 (log-rank test).(G) Kaplan-Meier survival curve of murine strains during starvation at 10 d after TAM. (*) P < 0.05 (log-rank test)





Emphasis

- Biostatistics collaborations lead to external grants, including K awards and funded IITs
- BSR has a wide spectrum of statistical expertise for cancer research including Bayesian designs for phase I/II trials, cluster randomized trials, causal inference
- BSR faculty biostatisticians are also faculty of Rutgers School of Public Health, providing opportunities for statistical methodology development, training and education


Future Directions


- Expand our expertise in several areas of critical needs for cancer research including:
 - statistical designs for phase I/II clinical trials
 - novel designs for population science and implementation science, data science, and
 - machine learning
- Actively recruit an additional 3 FTE faculty statisticians based on the strategic plan and needs-assessment approved by the CINJ Director






Utilization & Management








FY24 Chargeback Target: 25%

Satisfaction Survey for CY22 services



Participated: 14 of 57 members (25%)

Organization & Governance

BSR 6.3 FTE •

SRACs

- Advisory Committee meets annually
- Discusses operational and scientific progress
- SRM supports organization

SRM

- SR Faculty Directors report to the AD of SR
- SRM tracks and supports SRAC recommendations, productivity, service development, outreach

CINJ Director

- RLC
- Finance & Admin
- FAB





Supporting Information

